Inside Moderna’s Biggest mRNA Test Since COVID

Video summary

Moderna and Merck report positive Phase 3 melanoma results for an individualized mRNA vaccine added to Keytruda after a decade of development.

Moderna CEO Stéphane Bancel tells a16z’s Jorge Conde that Moderna and Merck’s personalized mRNA cancer treatment met its Phase 3 primary endpoint of recurrence-free survival in melanoma, and also its secondary endpoint of distant metastasis-free survival. In an earlier Phase 2 study, about 80% of patients were disease-free five years after treatment; Bancel hopes to file with regulators and make the treatment available as early as 2027. The vaccine compares tumor and healthy-cell DNA, then uses an algorithm to select up to 34 mutations and encode them in a patient-specific mRNA dose. Bancel says doses take about 42 days to produce, with a Massachusetts facility able to make tens of thousands annually. Moderna plans trials across other cancers, including lung, kidney, bladder, pancreatic and gastric cancers, while using Phase 3 patient data to improve its algorithm. He also describes future mRNA work in rare genetic liver diseases and autoimmune disease.

Chapters

1. 0:00How Moderna Went From COVID to Cancer: Personalized Tumor Sequencing and Phase 3 Melanoma News
2. 2:48The Phase 3 News: Moderna and Merck’s Melanoma Vaccine Meets Two Survival Endpoints
3. 5:46What Is Keytruda & Why Isn't It Enough Alone? Keytruda’s 60% Five-Year Result and Targeted T Cells
4. 9:23Preventing the Return of Cancer: The Vaccine Retrains Immunity to Recognize Missed Cancer Signals
5. 11:16Why 20 Years and 1,000 Trials Failed Before mRNA Worked: 34 Personalized Mutations and 90% Different Antigens
6. 15:09Inside the Algorithm: Moderna’s 10-Year-Old Neoantigen Model and Plans for Version 2.0
7. 18:48The Operational Lift of Making a Vaccine for Every Patient: Tailored Doses Versus CAR T Cell Engineering
8. 20:16Vein to Vein: Moderna’s 42-Day Personalized Vaccine Process and Factory-Efficiency Push
9. 24:33Manufacturing at Scale & the COGS Question: Marlborough Capacity and Undisclosed Pricing
10. 27:08How Do You Regulate a Medicine That's Different Every Time? Process BLA and Consistent Manufacturing
11. 29:37Beyond Melanoma: Moderna Targets Lung, Kidney, Bladder, Pancreatic, and Gastric Cancers
12. 35:58From COVID to Cancer to Autoimmune Disease: Moderna Advances Rare Liver and Personalized Treatments

What the full analysis includes

12 chapters · 57 key points · 12 section summaries · mind map

The remaining 54 key points, section summaries and mind map are in the full analysis. Analyze this video to see everything →

This video is 39 min. The Free plan analyzes videos up to 30 min; plans from Plus cover videos up to 2 hours.